Valuation: Altimmune, Inc.

Market Cap 568M 493M 458M 422M 796M 54.21B 810M 5.42B 2.12B 26.93B 2.13B 2.09B 90.55B P/E 2026 *
-4.83x
P/E 2027 * -4.44x
Enterprise Value 123M 107M 99.51M 91.77M 173M 11.78B 176M 1.18B 461M 5.85B 463M 453M 19.67B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Altimmune, Inc.

1 day+2.05%
1 week+4.93%
Current month-1.97%
1 month-1.97%
3 months+14.62%
6 months-46.79%
Current year-17.45%
1 week 2.8
Extreme 2.8
3.31
1 month 2.75
Extreme 2.75
3.31
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
2/26/26 A Free

Chief Technology Officer

318,100 0.2540%
2/26/26 A Free

Chief Financial Officer

370,000 0.2955%
1/31/26 A Free

Executive/Senior Manager

4,571 0.0044%
Change 5-day change 1-year change 3-year change Capi.($)
+2.05%+4.93%-18.36%-8.31% 568M
-0.81%-0.33%+27.15%+81.12% 55.6B
-3.74%-6.32%+42.70%+64.45% 55.2B
-0.11%+0.86%-15.63%-13.56% 23.51B
-1.58%-5.51%-3.51%+375.36% 22.35B
+1.59%-2.14%+14.97%-12.93% 20.6B
-1.23%-3.51%+25.70%-31.88% 17.45B
+1.54%-6.46%+25.53%+545.67% 15.16B
+1.16%+0.58%+51.87%+181.96% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -0.64%-1.00%+30.23%+145.41% 23.81B
Weighted average by Cap. -1.30%-0.45%+30.92%+125.40%

Financials

2026 *2027 *
Net sales - -
Net income -107M -92.9M -86.27M -79.56M -150M -10.21B -153M -1.02B -400M -5.07B -402M -393M -17.05B -130M -113M -105M -96.72M -182M -12.41B -185M -1.24B -486M -6.16B -488M -478M -20.73B
Net Debt -444M -386M -359M -331M -623M -42.44B -634M -4.24B -1.66B -21.08B -1.67B -1.63B -70.88B -340M -295M -274M -253M -476M -32.44B -485M -3.24B -1.27B -16.11B -1.28B -1.25B -54.18B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
30/07/26 $2.980 +2.05% 5,437,225
29/07/26 $2.920 -2.34% 8,301,360
28/07/26 $2.990 +1.01% 17,142,614
27/07/26 $2.960 +6.86% 4,060,013
24/07/26 $2.770 -2.46% 1,911,556
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.980USD
Average target price
17.22USD
Spread / Average Target
+477.93%

Quarterly revenue - Rate of surprise